Join us for a focused, practical session that serves as a guide to the increasingly complex Dutch reimbursement landscape and equips your team with the strategic knowledge needed to build a successful ZIN submission.

Drawing on deep expertise across NL market access strategy, HTA evidence requirements, and health-economic modelling, David and Jeanni walk you through the key stakeholders, pathways, and decision points that define success in the Netherlands — from early planning all the way through to reimbursement.

Why Attend: With ZIN submissions demanding rigorous clinical and economic evidence as part of a well-defined market access strategy, pharma teams must navigate a complex web of players, pathways, and timelines while aligning global and local deliverables. Submissions frequently fall short when evidence, clinical claims and positioning are misaligned, or economic models fail to meet NL-specific analytical standards. This session gives you the roadmap to get it right — from the first feasibility assessment to the final dossier.

Key Takeaways:

• NL Market Access Landscape: A clear overview of the key players (ZIN, VWS, ZN, and more), the intramural and extramural pathways to reimbursement, and how NL timelines align with EMA milestones — so you always know your next step in the process.

• ZIN Evidence Requirements: Understand exactly what ZIN expects clinically and economically — from clinical positioning, stakeholder planning, and GRADE assessment, to what it takes to build an economic model of sufficient quality that moves you to price negotiation.

• Your NL Access Roadmap: A practical, timeline-driven guide to what needs to happen and when — covering PICO mapping, publication and stakeholder strategy, model and dossier planning, and how to align your local NL activities with your global program.